Carisma: Carisma Therapeutics Announces Strategic Reprioritization Of Pipeline; To Cut Workforce By 34%
(RTTNews) - Carisma Therapeutics Inc. (CARM), a macrophage-focused therapeutics company, announced Monday a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%.
Read full article »
Carisma is a Pennsylvania-based biopharmaceutical company that researches and develops CAR-macrophage immunotherapies for the treatment of cancer.
Read more